OncoNano Medicine Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$10.1M
- Investors
-
7
OncoNano Medicine General Information
Description
Developer of a nanotechnology platform designed to improve the delivery and activation of cancer therapies in acidic tumor environments. The company offers an ultra pH-sensitive polymeric micelle system, which remains inactive in the bloodstream, enabling surgeons to treat advanced cancer patients to access safer and more effective treatment options with reduced side effects.
Contact Information
Website
www.onconano.comCorporate Office
- 3060 Pegasus Park Drive
- Suite 244
- Dallas, TX 75247
- United States
Corporate Office
- 3060 Pegasus Park Drive
- Suite 244
- Dallas, TX 75247
- United States
OncoNano Medicine Timeline
OncoNano Medicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC (Series B2) | 01-Oct-2026 | $10.1M | Completed | Clinical Trials - Phase 3 | ||
| 10. Later Stage VC (Series B) | 03-Jun-2025 | Completed | Clinical Trials - Phase 3 | |||
| 9. Later Stage VC (Series B) | 02-Nov-2021 | Completed | Clinical Trials - Phase 3 | |||
| 8. Later Stage VC (Series A) | 04-Sep-2020 | Completed | Clinical Trials - Phase 3 | |||
| 7. Grant | 20-Aug-2020 | Completed | Clinical Trials - Phase 3 | |||
| 6. Grant | 27-Aug-2019 | Completed | Product Development | |||
| 5. Grant | 01-Jan-2018 | Completed | Startup | |||
| 4. Grant | 21-Sep-2017 | Completed | Startup | |||
| 3. Grant | 01-Jan-2016 | $269K | Completed | Startup | ||
| 2. Grant | 01-Jan-2014 | $6M | Completed | Startup |
OncoNano Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B Prime | ||||||||
| Series B | 57,727,822 | $0.000100 | 6% | $0.34 | $0.34 | 1x | $0.34 | 10.18% |
| Series A | 42,471,030 | $0.000100 | 6% | $0.24 | $0.24 | 1x | $0.24 | 7.49% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
OncoNano Medicine Comparisons
Industry
Financing
Details
OncoNano Medicine Competitors (2)
One of OncoNano Medicine’s 2 competitors is RootPath, a Venture Capital-Backed company based in Framingham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| RootPath | Venture Capital-Backed | Framingham, MA | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA |
OncoNano Medicine Patents
OncoNano Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026050709-A1 | Methods of treating cancer with polyvalent sting activating compositions and pd-1 inhibitors | Pending | 29-Aug-2024 | ||
| AU-2023371676-A1 | Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines | Pending | 06-Nov-2022 | ||
| EP-4611726-A2 | Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines | Pending | 06-Nov-2022 | ||
| EP-4611726-A4 | Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines | Pending | 06-Nov-2022 | ||
| US-20240165026-A1 | Protonated ph responsive polymer encapsulation of bispecific antibodies and cytokines | Pending | 06-Nov-2022 | A61K47/34 |
OncoNano Medicine Signals
OncoNano Medicine Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advantech Capital Partners | PE/Buyout | Minority | ||
| AG Collective Capital | Venture Capital | Minority | ||
| CKG Management | Venture Capital | Minority | ||
| Green Park & Golf Ventures | Venture Capital | Minority | ||
| Houston Angel Network | Angel Group | Minority |
OncoNano Medicine FAQs
-
When was OncoNano Medicine founded?
OncoNano Medicine was founded in 2014.
-
Where is OncoNano Medicine headquartered?
OncoNano Medicine is headquartered in Dallas, TX.
-
What is the size of OncoNano Medicine?
OncoNano Medicine has 22 total employees.
-
What industry is OncoNano Medicine in?
OncoNano Medicine’s primary industry is Drug Discovery.
-
Is OncoNano Medicine a private or public company?
OncoNano Medicine is a Private company.
-
What is the current valuation of OncoNano Medicine?
The current valuation of OncoNano Medicine is .
-
What is OncoNano Medicine’s current revenue?
The current revenue for OncoNano Medicine is .
-
How much funding has OncoNano Medicine raised over time?
OncoNano Medicine has raised $127M.
-
Who are OncoNano Medicine’s investors?
Advantech Capital Partners, AG Collective Capital, CKG Management, Green Park & Golf Ventures, and Houston Angel Network are 5 of 7 investors who have invested in OncoNano Medicine.
-
Who are OncoNano Medicine’s competitors?
RootPath and TScan Therapeutics are competitors of OncoNano Medicine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process